A citation-based method for searching scientific literature

Krishna L Kanchi, Kimberly J Johnson, Charles Lu, Michael D McLellan, Mark D M Leiserson, Michael C Wendl, Qunyuan Zhang, Daniel C Koboldt, Mingchao Xie, Cyriac Kandoth, Joshua F McMichael, Matthew A Wyczalkowski, David E Larson, Heather K Schmidt, Christopher A Miller, Robert S Fulton, Paul T Spellman, Elaine R Mardis, Todd E Druley, Timothy A Graubert, Paul J Goodfellow, Benjamin J Raphael, Richard K Wilson, Li Ding. Nat Commun 2014
Times Cited: 174



Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn, Yang Li, Jie Li, Ana Maria Gonzalez-Angulo, Karen Smith McCune, Maurie Markman, Russell R Broaddus, Jerry S Lanchbury, Karen H Lu, Gordon B Mills. J Clin Oncol 2010
Times Cited: 240




List of shared articles



Times cited

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer.
Yan You, Lei Li, Junliang Lu, Huanwen Wu, Jing Wang, Jie Gao, Ming Wu, Zhiyong Liang. Front Oncol 2020
4

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.
C├ęcile Le Page, Setor Amuzu, Kurosh Rahimi, Walter Gotlieb, Jiannis Ragoussis, Patricia N Tonin. Semin Cancer Biol 2020
6

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Razan Sheta, Magdalena Bachvarova, Marie Plante, Marie-Claude Renaud, Alexandra Sebastianelli, Jean Gregoire, Jamilet Miranda Navarro, Ricardo Bringas Perez, Jean-Yves Masson, Dimcho Bachvarov. J Transl Med 2020
0

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Robert D Morgan, Andrew R Clamp, D Gareth R Evans, Richard J Edmondson, Gordon C Jayson. Cancer Chemother Pharmacol 2018
38

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Gillian E Hanley, Jessica N McAlpine, Dianne Miller, David Huntsman, Kasmintan A Schrader, C Blake Gilks, Gillian Mitchell. BMC Cancer 2018
10

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Robbert D A Weren, Arjen R Mensenkamp, Michiel Simons, Astrid Eijkelenboom, Aisha S Sie, Hicham Ouchene, Monique van Asseldonk, Encarna B Gomez-Garcia, Marinus J Blok, Joanne A de Hullu,[...]. Hum Mutat 2017
40